D ESPITE CONSIDERABLE advances in the treatment of hemophilia, clinical expertise in hemophilia care is often concentrated within hemophilia treatment centers. These centers directly and indirectly care for most patients with hemophilia, and provide sophisticated services to this patient population. Much as bone marrow transplantation (BMT) and transfusion medicine have earned a special niche i...

OBJECTIVE To examine the direct and indirect costs of hemophilia care among persons with hemophilia A in the US. METHODS Observational data were obtained from HUGS-Va, a multi-center study from six federally supported hemophilia treatment centers (HTCs). Eligible individuals completed a standardized initial questionnaire and were followed regularly for 2 years to obtain information on work or...

INTRODUCTION New longer-acting factor products will potentially allow for less frequent infusion in prophylactic treatment of hemophilia. However, the role of administration frequency relative to other treatment attributes in determining preferences for prophylactic hemophilia treatment regimens is not well understood. AIM To identify the relative importance of frequency of administration, ef...

Hemophilia is an inherited X-linked coagulopathy defined by a deficiency or abnormality in the clotting function of factor VIII (Hemophilia A) IX B). Prophylaxis – regular administration therapeutic products to maintain hemostasis and prevent bleeding mainstream treatment. Addressing development scientific evidence for administrating prophylaxis goal this review. modality choice people with sev...

background bone marrow transplantation (bmt)is nowadays used in various hematological disorders including leukemias. hemophilia a & b are sex linked bleeding disorders in which there are various genetic abnormalities in factor viii & ix genes. among various hematological disorders, bleeding disorders mainly hemophilia in now widely treated using plasma derived and recombinant factor viii & ix c...

Hemophilia is an X-linked recessive bleeding disorder caused by deficiency of FVIII (hemophilia A) or FIX (hemophilia B). Mutations in the FVIII or FIX genes, both located on the long arm of the X chromosome, are detectable in the majority of cases of hemophilia A or B, respectively. During normal hemostasis, FVIII and FIX form an enzymatic complex; thus, deficiency of either protein leads to a...

Objective: Hemophilia is a genetic bleeding disorder results from a deficient in synthesis of a protein needed for blood clotting. The number of people with hemophilia in the United States is about 20,000. Iran having the ninth largest Hemophilia population in the world. Hemophilia lead to many psychological and physiological complications. Therefore, this study aimed to evaluate the effectiven...

conclusions vaccination of non-immune individuals against hav infection in high risk groups especially hemophilia and thalassemia patients is recommended. results did not show any differences about seroprevalence of hev among iranian general population. results anti-hav igg antibodies were observed more frequently in thalassemia patients (60/64; 93.8%) than in hemophilia patients (104/155; 67.1...

Improvements in hemophilia care and antiviral treatments have resulted in increases in median life expectancy for persons with congenital hemophilia A and B. Currently, 2% of hemophilia A and B patients surveyed in US comprehensive hemophilia treatment centers are 65 years of age or older and 15% are 45 years or older. Many of the complications of hemophilia, including intracranial hemorrhage, ...

Having a healthy life is the right of every human being. The State has to help people live and support suffering from any disease. In this article, researcher focuses on one diseases called Hemophilia. Hemophilia bleeding genetic disorder. It included in Rights People with Disability Act, 2016. highly neglected There no research legal perspective topic. This paper will understand hemophilia gap...